Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. EKIMAS Corporation
  6. News
  7. Summary
    ASNB   US28265K1060

EKIMAS CORPORATION

(ASNB)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EKIMAS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

01/14/2022 | 02:02pm EST

Cautionary Note Regarding Forward-Looking Statements

This Report on Form 10-Q contains certain statements that are "forward-looking" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Litigation Reform Act"). These forward looking statements and other information are based on our beliefs as well as assumptions made by us using information currently available.

The words "anticipate," "believe," "estimate," "expect," "intend," "will," "should" and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or using other similar expressions.

In accordance with the provisions of the Litigation Reform Act, we are making investors aware that such forward-looking statements, because they relate to future events, are by their very nature subject to many important factors that could cause actual results to differ materially from those contemplated by the forward-looking statements contained in this Report on Form 10-Q. For example, given the cessation of our operations as a developer, manufacturer, marketer and seller of advanced polymers on January 31, 2020, resulting from the sale of substantially all of our assets to an independent third party, we became engaged in efforts to identify either an (i) operating company to acquire or merge with through an equity-based exchange transaction or (ii) investor interested in purchasing a majority interest in our common stock, whereby either transaction would likely result in a change in control. If we are unable to effect a transaction with an operating company or investor, we may be required to cease all operations, including liquidation through bankruptcy proceedings. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date hereof. You are encouraged to review our filings with the Securities and Exchange Commission and to read and carefully consider the additional information included in our Annual Report on Form 10K for the fiscal year ended March 31, 2021, including but not limited to the Risk Factors discussed in Part I, Item 1A. We assume no responsibility to update any forward-looking statements as a result of new information, future events, or otherwise except as required by law.




Business



On January 31, 2020 (the "Closing Date"), we completed the sale of substantially all of our assets (the "Asset Sale") for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation ("MCPP"). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

Management is seeking to identify an operating company and engage in a merger or business combination of some kind, or acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements to merge with an operating company.

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target's management to have proven its abilities or effectiveness, or the lack of an established market for the target's products or services, or the inability to reach profitability in the next few years.



13






Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.



Critical Accounting Policies


Our critical accounting policies are summarized in Note 3 to our financial statements included in Item 8 of our annual report on Form 10-K for the fiscal year ended March 31, 2021. However, certain of our accounting policies require the application of significant judgment by our management, and such judgments are reflected in the amounts reported in our financial statements. In applying these policies, our management uses its judgment to determine the appropriate assumptions to be used in the determination of estimates. Those estimates are based on our historical experience, terms of existing contracts, our observance of market trends, information provided by our strategic partners and information available from other outside sources, as appropriate. Actual results may differ significantly from the estimates contained in our unaudited financial statements. There have been no changes to our critical accounting policies during the fiscal quarter ended December 31, 2021.



Results of Operations


Three Months Ended December 31, 2021 vs. December 31, 2020



Operating Expenses


During the three months ended December 31, 2021, our operating expenses were approximately $40,000 as compared with $53,000 for the comparable prior year period, a decrease of approximately $13,000, or 24.5%. Our operating expenses are composed of those costs necessary to operate a public company, which are primarily composed of management consultant fees, accounting fees, professional fees, and regulatory fees. The decrease in these operating costs is primarily a result of decreased accounting and management advisory fees which were reduced in connection with the sale of shares to a private investor.

Nine Months Ended December 31, 2021 vs. December 31, 2020



Operating Expenses


During the nine months ended December 31, 2021, our operating expenses were approximately $256,000 as compared with $226,000 for the comparable prior year period, an increase of approximately $30,000, or 13.3%. Our operating expenses are composed of those costs necessary to operate a public company, which are primarily composed of management consultant fees, accounting fees, professional fees, and regulatory fees. The increase in these operating costs is primarily a result of increased accounting fees in connection with the preparation and filing of financial statements with regulatory agencies, and consulting fees in connection with the evaluation of potential merger candidates.



Other Income


On May 20, 2021, we received a $22,000 cash deposit (the "Deposit") in connection with a non-binding arrangement entered into with a private company having an interest in a potential business combination with us. On August 12, 2021, we were notified by the private company of their intent to terminate the arrangement. The arrangement provided that the Deposit was refundable, net of all reasonable legal, advisory and regulatory fees incurred by us. Our legal, advisory and regulatory fees exceeded the amount of the Deposit, accordingly, there was no refund due to the private company.



14






Liquidity and Capital Resources

As of December 31, 2021, we had cash of approximately $122,000 as compared to a cash balance of approximately $128,000 as of March 31, 2021.

During the nine months ended December 31, 2021, we had net cash of approximately $206,000 used in operating activities. Our cash flows used in operating activities is primarily a result of our net loss of approximately $234,000 which was offset by an increase in accounts payable and accrued expense of approximately $28,000. During the nine months ended December 31, 2020, we had net cash of approximately $272,000 used in operating activities. Our cash flows used in operating activities was primarily due to our (i) net loss of approximately $226,000; (ii) increase in aggregate accounts payable and accrued expenses of approximately $38,000; and (iii) increases in customer advances of approximately $69,000. These uses of cash in operating activities were offset by collections of accounts receivable of approximately $63,000.

During the nine months ended December 31, 2021, we had net cash of $200,000 provided by financing activities which was a result of the issuance of an additional 21,136,250 shares of our common stock to a private investor in consideration of $200,000 in cash. During the nine months ended December 31, 2020, we had net cash of approximately $5,087,000 used in financing activities as a result of the cash distribution of approximately $5,087,000 on April 23, 2020 to our stockholders of record as of April 16, 2020.

On January 31, 2020 (the "Closing Date"), we completed the sale of substantially all of our assets (the "Asset Sale") for a total gross purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation ("MCPP"). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify potential operating companies interested in merging into us through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not resulted in the execution of a definitive agreement to consummate such a transaction, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the three and nine months ended December 31, 2021, we reported a net loss of approximately $40,000 and $234,000, respectively. Cash flows of approximately $206,000 and $272,000 were used in operations for the nine months ended December 31, 2021 and 2020, respectively. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, management believes there is substantial doubt about our ability to continue as a going concern.

Management is seeking to identify an operating company for the purpose of effecting a merger or business combination, or to acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements to merge with an operating company.

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target's management to have proven its abilities or effectiveness, or the lack of an established market for the target's products or services, or the inability to reach profitability in the next few years.

Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.



15







Commitments


We do not have any long-term commitments as of December 31, 2021.

Off-Balance Sheet Arrangements

As of December 31, 2021, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

© Edgar Online, source Glimpses

All news about EKIMAS CORPORATION
01/14EKIMAS CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
01/14EKIMAS Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
2021EKIMAS CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
2021EKIMAS Corporation Reports Earnings Results for the Second Quarter and Six Months Ended..
CI
2021EKIMAS CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu..
AQ
2021EKIMAS Corporation Announces CEO Changes
CI
2021EKIMAS Corporation Announces Director Changes
CI
2021EKIMAS : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
2021EKIMAS : Management's Discussion and Analysis or Plan of Operation (form 10-K)
AQ
2021EKIMAS : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,33 M - -
Net cash 2021 0,13 M - -
P/E ratio 2021 -2,19x
Yield 2021 -
Capitalization 1,53 M 1,53 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 41,9%
Chart EKIMAS CORPORATION
Duration : Period :
EKIMAS Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Bennett J. Yankowitz Chief Executive Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
EKIMAS CORPORATION53.09%2
ABBOTT LABORATORIES-10.44%216 172
MEDTRONIC PLC4.17%144 890
BECTON, DICKINSON AND COMPANY4.93%75 214
HOYA CORPORATION-12.71%48 228
BAXTER INTERNATIONAL INC.-0.28%42 859